These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38626563)

  • 41. Effects of Mu-Opiate Receptor Gene Polymorphism rs1799971 (A118G) on the Antidepressant and Dissociation Responses in Esketamine Nasal Spray Clinical Trials.
    Saad Z; Hibar D; Fedgchin M; Popova V; Furey ML; Singh JB; Kolb H; Drevets WC; Chen G
    Int J Neuropsychopharmacol; 2020 Dec; 23(9):549-558. PubMed ID: 32367114
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.
    Zhdanava M; Teeple A; Pilon D; Shah A; Caron-Lapointe G; Joshi K
    J Med Econ; 2023; 26(1):691-700. PubMed ID: 37130075
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?
    d'Andrea G; Pettorruso M; Lorenzo GD; Mancusi G; McIntyre RS; Martinotti G
    Eur Neuropsychopharmacol; 2023 May; 70():49-55. PubMed ID: 36867895
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and Tolerability of Two Novel "Standard of Care" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study.
    Gutierrez G; Rosenblat J; Hawken E; Swainson J; Vazquez G
    JMIR Res Protoc; 2022 May; 11(5):e34711. PubMed ID: 35604752
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3.
    Ochs-Ross R; Daly EJ; Zhang Y; Lane R; Lim P; Morrison RL; Hough D; Manji H; Drevets WC; Sanacora G; Steffens DC; Adler C; McShane R; Gaillard R; Wilkinson ST; Singh JB
    Am J Geriatr Psychiatry; 2020 Feb; 28(2):121-141. PubMed ID: 31734084
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of subcutaneous esketamine on blood pressure and heart rate in treatment-resistant depression.
    Del Sant LC; Sarin LM; Magalhães EJM; Lucchese AC; Tuena MA; Nakahira C; Fava VAR; Delfino R; Surjan J; Steiglich MS; Barbosa M; Abdo G; Cohrs FM; Liberatori A; Del Porto JA; Lacerda ALT; de Jesus Mari J
    J Psychopharmacol; 2020 Oct; 34(10):1155-1162. PubMed ID: 32638662
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.
    Smith-Apeldoorn SY; Veraart JKE; Kamphuis J; van Asselt ADI; Touw DJ; Aan Het Rot M; Schoevers RA
    BMC Psychiatry; 2019 Nov; 19(1):375. PubMed ID: 31783823
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension.
    Smith-Apeldoorn SY; Veraart JKE; Kamphuis J; Spijker J; van der Meij A; van Asselt ADI; Aan Het Rot M; Schoevers RA
    Mol Psychiatry; 2024 Sep; 29(9):2657-2665. PubMed ID: 38523183
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical experiences with intranasal esketamine for major depressive disorder resistant to treatment and with a psychiatric emergency: case presentations.
    Pompili M; Sarli G; Erbuto D; Manfredi G; Comparelli A
    Int Clin Psychopharmacol; 2023 May; 38(3):195-200. PubMed ID: 36630183
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The efficacy and safety of adjunctive intranasal esketamine treatment in major depressive disorder: a systematic review and meta-analysis.
    Jawad MY; Di Vincenzo JD; Ceban F; Jaberi S; Lui LMW; Gillissie ES; Alnafeesi Y; Rosenblat JD; McIntyre RS
    Expert Opin Drug Saf; 2022 Jun; 21(6):841-852. PubMed ID: 35387538
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant.
    Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J
    J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study.
    Ludwig VM; Sauer C; Young AH; Rucker J; Bauer M; Findeis H; Ritter P
    CNS Drugs; 2021 Aug; 35(8):881-892. PubMed ID: 34283390
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of Repeated Intravenous Esketamine on Adolescents With Major Depressive Disorder and Suicidal Ideation: A Randomized Active-Placebo-Controlled Trial.
    Zhou Y; Lan X; Wang C; Zhang F; Liu H; Fu L; Li W; Ye Y; Hu Z; Chao Z; Ning Y
    J Am Acad Child Adolesc Psychiatry; 2024 May; 63(5):507-518. PubMed ID: 37414272
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Esketamine for Unipolar Major Depression With Psychotic Features: A Retrospective Chart Review and Comparison With Nonpsychotic Depression.
    Souza-Marques B; Telles M; Leal GC; Faria-Guimarães D; Correia-Melo FS; Jesus-Nunes AP; Vieira F; Souza L; Lins-Silva D; Mello RP; Guerreiro-Costa L; Bandeira ID; Lacerda ALT; Sampaio AS; Quarantini LC
    J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):408-412. PubMed ID: 35727083
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination of Acute and Maintenance Esketamine Treatment With Adjunctive Long-Term Vagus Nerve Stimulation in Difficult-to-Treat Depression.
    Kavakbasi E; Baune BT
    Neuromodulation; 2024 Jun; 27(4):766-773. PubMed ID: 38340111
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice.
    Vazquez G; Gutierrez G; Rosenblat J; Schaffer A; Swainson J; Karthikeyan G; Ravindran N; Lam RW; Do A; Giacobbe P; Hawken E; Milev R
    BMJ Open; 2022 Sep; 12(9):e060967. PubMed ID: 36581972
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans.
    Joshi K; Pilon D; Shah A; Holiday C; Karkare S; Zhdanava M
    J Med Econ; 2023; 26(1):422-429. PubMed ID: 36924214
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
    Fu DJ; Ionescu DF; Li X; Lane R; Lim P; Sanacora G; Hough D; Manji H; Drevets WC; Canuso CM
    J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32412700
    [TBL] [Abstract][Full Text] [Related]  

  • 59. At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study.
    Cepeda MS; Kern DM; Canuso CM
    Depress Anxiety; 2021 May; 38(5):521-527. PubMed ID: 33475213
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review.
    Wong S; Kwan ATH; Teopiz KM; Le GH; Meshkat S; Ho R; d'Andrea G; Cao B; Di Vincenzo JD; Rosenblat JD; McIntyre RS
    J Affect Disord; 2024 Apr; 350():698-705. PubMed ID: 38244804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.